OXFORD, England, Oct. 18 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced that the UK Intellectual Property Office (IPO) has rejected a revocation action brought by Biogene against three patents licensed exclusively to Enigma by the Defence Science and Technology Laboratory (Dstl), part of the UK Ministry of Defence. The patents cover electrically conducting polymer (ECP) thermal cycling technology which is used in Enigma's fully automated real-time PCR system, the Enigma ML, to enable rapid molecular testing at the point of care.
On 9th August 2010 the IPO issued summary judgement against Biogene and awarded costs to Dstl. The absence of any subsequent appeal to the High Court means that these patents are now free from any challenge.
The ECP patents are part of Enigma's extensive intellectual property portfolio, covering molecular diagnostics and sample preparation technologies, which comprises of over 350 patent filings including 220 granted cases.
About Enigma Diagnostics Limited
Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Enigma's innovative and proprietary technologies combine the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.
For more information visit www.enigmadiagnostics.com
+971 (0)4 446 2367
SOURCE Enigma Diagnostics Limited